Amylyx stock soars on GLP-1 success: here's why investors should sell
Covered by 1 source · 1 article
Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm’s…
Covered by
